Epic Sciences

Press Releases

06.28.2018

Blood Test Predicts Treatment Response and Survival for Patients with Metastatic Prostate Cancer

Testing could lead to extension of life through improved clinical decision-making by identifying patients who need to switch from targeted hormonal therapy to chemotherapy

05.22.2018

Epic Sciences Presents Single Cell Genomics Data at 10th DIA China Annual Meeting

New data demonstrates the detection of tumor mutational burden and chromosomal instability in single circulating tumor cells to develop cancer diagnostic tests for guiding immuno-oncology clinical development and decision-making.

05.16.2018

Epic Sciences and Its Collaborators to Present New Data at ASCO 2018

New data validates clinical utility of commercially-available Oncotype DX® AR-V7 Nucleus Detect™ test and additional tests under development for predictive medicine

05.11.2018

Epic Sciences Presents Detection and Characterization of Rare Peripheral CTC Immunogenicity and T-Cell Activation

At the 2018 AACR annual meeting, Epic Sciences presented data from two studies demonstrating the company’s “No Cell Left Behind” detection platform’s capability to analyze potential markers of response to immuno-oncology (IO) agents, such as checkpoint inhibitors, vaccines, and CAR-T therapies.

03.30.2018

Epic Sciences and Genomic Health Announce Favorable Draft Local Coverage Determination (LCD) on Medicare Coverage for Use of the Oncotype DX® AR-V7 Nucleus Detect™ Test in Patients with Metastatic Castration-Resistant Prostate Cancer

Medicare Draft Coverage Supports Clinical Utility of the Oncotype DX AR-V7 Nucleus Detect Test, Providing 25,000 Medicare Patients with Coverage Once LCD Is Finalized

More Press Releases

In the News

07.07.2016

Genomic Health to market Epic Sciences’ AR-V7 liquid biopsy test.

New York, GenomeWeb — Genomic Health and Epic Sciences today announced that they have signed an exclusive agreement under which Genomic Health will commercialize Epic Sciences' AR-V7 liquid biopsy test in the United States.

07.06.2016

Test aids prostate cancer treatment.

New York, Wall Street Journal — Genomic Health Inc. has struck a deal to commercialize a new blood test that can help advanced prostate cancer patients decide whether to try costly new-generation drugs or rely on much cheaper traditional chemotherapy to improve their chances for survival.

06.14.2016

Guest Commentary: Back to cancer’s drawing board.

By Murali Prahalad of Epic Sciences — A curious problem arises for each new precision oncology therapeutic with a companion diagnostic: Many predicted responders exhibit primary resistance.

06.09.2016

Epic Sciences' circulating tumor cell prostate cancer test shows promise in new JAMA study.

Chicago, GenomeWeb — A new study by researchers from Memorial Sloan Kettering Cancer Center has demonstrated the predictive power of an AR-V7 protein expression test using Epic Sciences' non-EPCAM-based circulating tumor cell detection platform, which could help guide treatment decisions for men with metastatic castration-resistant prostate cancer.

01.28.2016

Epic, Avera ink deal to use liquid biopsy platform in clinical studies.

New York, GenomeWeb — Epic Sciences and Avera Medical announced today that they have signed a deal under which the healthcare network will use the company's circulating tumor cell (CTC)-detection and -analysis platform in upcoming clinical studies of precision cancer therapies.

More News